APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Cancer Anorexia-Cachexia Syndrome Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cancer Anorexia-Cachexia Syndrome Drug Market Outlook and Growth Opportunities 2026

Report ID 173974180419 December 2025191 pages

Choose your research edition.

Industry ResearchCancer Anorexia-Cachexia Syndrome Drug Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Anorexia-Cachexia Syndrome Drug Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Cancer Anorexia-Cachexia Syndrome Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Anorexia-Cachexia Syndrome Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Anorexia-Cachexia Syndrome Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Cancer Anorexia-Cachexia Syndrome Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cancer Anorexia-Cachexia Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cancer Anorexia-Cachexia Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Anorexia-Cachexia Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cancer Anorexia-Cachexia Syndrome Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cancer Anorexia-Cachexia Syndrome Drug market include Novartis AG, Viking Therapeutics Inc, RaQualia Pharma Inc, PsiOxus Therapeutics Ltd, Obexia AG, Lakewood-Amedex Inc, Incyte Corp, Aphios Corp and Aeterna Zentaris Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cancer Anorexia-Cachexia Syndrome Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cancer Anorexia-Cachexia Syndrome Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cancer Anorexia-Cachexia Syndrome Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cancer Anorexia-Cachexia Syndrome Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Cancer Anorexia-Cachexia Syndrome Drug Segment by Company

Novartis AG

Viking Therapeutics Inc

RaQualia Pharma Inc

PsiOxus Therapeutics Ltd

Obexia AG

Lakewood-Amedex Inc

Incyte Corp

Aphios Corp

Aeterna Zentaris Inc

Acacia Pharma Ltd

Cancer Anorexia-Cachexia Syndrome Drug Segment by Type

NEO-1940

Foxo1-nRNA

DLN-101

C-1889

AVGN-7

Others

Cancer Anorexia-Cachexia Syndrome Drug Segment by Application

Hospital

Clinic

Others

Cancer Anorexia-Cachexia Syndrome Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Cancer Anorexia-Cachexia Syndrome Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Cancer Anorexia-Cachexia Syndrome Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cancer Anorexia-Cachexia Syndrome Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Cancer Anorexia-Cachexia Syndrome Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Anorexia-Cachexia Syndrome Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Anorexia-Cachexia Syndrome Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Anorexia-Cachexia Syndrome Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cancer Anorexia-Cachexia Syndrome Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cancer Anorexia-Cachexia Syndrome Drug industry.

Chapter 3: Detailed analysis of Cancer Anorexia-Cachexia Syndrome Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Cancer Anorexia-Cachexia Syndrome Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Cancer Anorexia-Cachexia Syndrome Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cancer Anorexia-Cachexia Syndrome Drug Industry Trends Table 2. Cancer Anorexia-Cachexia Syndrome Drug Industry Drivers Table 3. Cancer Anorexia-Cachexia Syndrome Drug Industry Opportunities and Challenges Table 4. Cancer Anorexia-Cachexia Syndrome Drug Industry Restraints Table 5. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue Share by Company (2021-2026) Table 7. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume Share by Company (2021-2026) Table 9. Global Cancer Anorexia-Cachexia Syndrome Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Cancer Anorexia-Cachexia Syndrome Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Cancer Anorexia-Cachexia Syndrome Drug Key Company Manufacturing Base & Headquarters Table 12. Global Cancer Anorexia-Cachexia Syndrome Drug Company, Product Type & Application Table 13. Global Cancer Anorexia-Cachexia Syndrome Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Cancer Anorexia-Cachexia Syndrome Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of NEO-1940 Table 18. Significant Companies of Foxo1-nRNA Table 19. Significant Companies of DLN-101 Table 20. Significant Companies of C-1889 Table 21. Significant Companies of AVGN-7 Table 22. Significant Companies of Others Table 23. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume by Type (2021-2026) & (K Units) Table 25. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume by Type (2027-2032) & (K Units) Table 26. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume Share by Type (2021-2026) Table 27. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume Share by Type (2027-2032) Table 28. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type (2021-2026) Table 32. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Hospital Table 34. Significant Companies of Clinic Table 35. Significant Companies of Others Table 36. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume by Application (2021-2026) & (K Units) Table 38. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume by Application (2027-2032) & (K Units) Table 39. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume Share by Application (2021-2026) Table 40. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume Share by Application (2027-2032) Table 41. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application (2021-2026) Table 45. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application (2027-2032) Table 46. Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Region (2021-2026) & (K Units) Table 48. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Market Share by Region (2021-2026) Table 49. Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Region (2027-2032) & (K Units) Table 50. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Market Share by Region (2027-2032) Table 51. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Region (2021-2026) Table 54. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Region (2027-2032) Table 56. Global Cancer Anorexia-Cachexia Syndrome Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Cancer Anorexia-Cachexia Syndrome Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 61. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Market Share by Country (2021-2026) Table 62. Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Country (2027-2032) & (K Units) Table 63. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Market Share by Country (2027-2032) Table 64. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value Market Share by Country (2021-2026) Table 66. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value Market Share by Country (2027-2032) Table 68. Novartis AG Company Information Table 69. Novartis AG Business Overview Table 70. Novartis AG Cancer Anorexia-Cachexia Syndrome Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Novartis AG Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio Table 72. Novartis AG Recent Development Table 73. Viking Therapeutics Inc Company Information Table 74. Viking Therapeutics Inc Business Overview Table 75. Viking Therapeutics Inc Cancer Anorexia-Cachexia Syndrome Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Viking Therapeutics Inc Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio Table 77. Viking Therapeutics Inc Recent Development Table 78. RaQualia Pharma Inc Company Information Table 79. RaQualia Pharma Inc Business Overview Table 80. RaQualia Pharma Inc Cancer Anorexia-Cachexia Syndrome Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. RaQualia Pharma Inc Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio Table 82. RaQualia Pharma Inc Recent Development Table 83. PsiOxus Therapeutics Ltd Company Information Table 84. PsiOxus Therapeutics Ltd Business Overview Table 85. PsiOxus Therapeutics Ltd Cancer Anorexia-Cachexia Syndrome Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. PsiOxus Therapeutics Ltd Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio Table 87. PsiOxus Therapeutics Ltd Recent Development Table 88. Obexia AG Company Information Table 89. Obexia AG Business Overview Table 90. Obexia AG Cancer Anorexia-Cachexia Syndrome Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Obexia AG Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio Table 92. Obexia AG Recent Development Table 93. Lakewood-Amedex Inc Company Information Table 94. Lakewood-Amedex Inc Business Overview Table 95. Lakewood-Amedex Inc Cancer Anorexia-Cachexia Syndrome Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Lakewood-Amedex Inc Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio Table 97. Lakewood-Amedex Inc Recent Development Table 98. Incyte Corp Company Information Table 99. Incyte Corp Business Overview Table 100. Incyte Corp Cancer Anorexia-Cachexia Syndrome Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Incyte Corp Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio Table 102. Incyte Corp Recent Development Table 103. Aphios Corp Company Information Table 104. Aphios Corp Business Overview Table 105. Aphios Corp Cancer Anorexia-Cachexia Syndrome Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Aphios Corp Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio Table 107. Aphios Corp Recent Development Table 108. Aeterna Zentaris Inc Company Information Table 109. Aeterna Zentaris Inc Business Overview Table 110. Aeterna Zentaris Inc Cancer Anorexia-Cachexia Syndrome Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Aeterna Zentaris Inc Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio Table 112. Aeterna Zentaris Inc Recent Development Table 113. Acacia Pharma Ltd Company Information Table 114. Acacia Pharma Ltd Business Overview Table 115. Acacia Pharma Ltd Cancer Anorexia-Cachexia Syndrome Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Acacia Pharma Ltd Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio Table 117. Acacia Pharma Ltd Recent Development Table 118. Key Raw Materials Table 119. Raw Materials Key Suppliers Table 120. Cancer Anorexia-Cachexia Syndrome Drug Distributors List Table 121. Cancer Anorexia-Cachexia Syndrome Drug Customers List Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Cancer Anorexia-Cachexia Syndrome Drug Product Image Figure 2. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Cancer Anorexia-Cachexia Syndrome Drug Sales (2021-2032) & (K Units) Figure 5. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Cancer Anorexia-Cachexia Syndrome Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. NEO-1940 Image Figure 10. Foxo1-nRNA Image Figure 11. DLN-101 Image Figure 12. C-1889 Image Figure 13. AVGN-7 Image Figure 14. Others Image Figure 15. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume Share by Type (2021-2032) Figure 18. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type (2021-2032) Figure 21. Hospital Image Figure 22. Clinic Image Figure 23. Others Image Figure 24. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume Share by Application (2021-2032) Figure 27. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application (2021-2032) Figure 30. Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 31. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Cancer Anorexia-Cachexia Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 35. North America Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Cancer Anorexia-Cachexia Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Cancer Anorexia-Cachexia Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Cancer Anorexia-Cachexia Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 41. South America Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Cancer Anorexia-Cachexia Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Cancer Anorexia-Cachexia Syndrome Drug Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Cancer Anorexia-Cachexia Syndrome Drug Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • NEO-1940
  • Foxo1-nRNA
  • DLN-101
  • C-1889
  • AVGN-7
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis AG
  • Viking Therapeutics Inc
  • RaQualia Pharma Inc
  • PsiOxus Therapeutics Ltd
  • Obexia AG
  • Lakewood-Amedex Inc
  • Incyte Corp
  • Aphios Corp
  • Aeterna Zentaris Inc
  • Acacia Pharma Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value (2021-2032)
  4. 1.2.2 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Cancer Anorexia-Cachexia Syndrome Drug Market Dynamics
  1. 2.1 Cancer Anorexia-Cachexia Syndrome Drug Industry Trends
  2. 2.2 Cancer Anorexia-Cachexia Syndrome Drug Industry Drivers
  3. 2.3 Cancer Anorexia-Cachexia Syndrome Drug Industry Opportunities and Challenges
  4. 2.4 Cancer Anorexia-Cachexia Syndrome Drug Industry Restraints
3 Cancer Anorexia-Cachexia Syndrome Drug Market by Company
  1. 3.1 Global Cancer Anorexia-Cachexia Syndrome Drug Company Revenue Ranking in 2025
  2. 3.2 Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Company (2021-2026)
  3. 3.3 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Cancer Anorexia-Cachexia Syndrome Drug Average Price by Company (2021-2026)
  5. 3.5 Global Cancer Anorexia-Cachexia Syndrome Drug Company Ranking (2024-2026)
  6. 3.6 Global Cancer Anorexia-Cachexia Syndrome Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Cancer Anorexia-Cachexia Syndrome Drug Company Product Type and Application
  8. 3.8 Global Cancer Anorexia-Cachexia Syndrome Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Cancer Anorexia-Cachexia Syndrome Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Cancer Anorexia-Cachexia Syndrome Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Cancer Anorexia-Cachexia Syndrome Drug Market by Type
  1. 4.1 Cancer Anorexia-Cachexia Syndrome Drug Type Introduction
  2. 4.1.1 NEO-1940
  3. 4.1.2 Foxo1-nRNA
  4. 4.1.3 DLN-101
  5. 4.1.4 C-1889
  6. 4.1.5 AVGN-7
  7. 4.1.6 Others
  8. 4.2 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume by Type
  9. 4.2.1 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Type
  13. 4.3.1 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Type (2021-2032)
  15. 4.3.3 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type (2021-2032)
5 Cancer Anorexia-Cachexia Syndrome Drug Market by Application
  1. 5.1 Cancer Anorexia-Cachexia Syndrome Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume by Application
  6. 5.2.1 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Application
  10. 5.3.1 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application (2021-2032)
6 Cancer Anorexia-Cachexia Syndrome Drug Regional Sales and Value Analysis
  1. 6.1 Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Region (2027-2032)
  5. 6.3 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Cancer Anorexia-Cachexia Syndrome Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Cancer Anorexia-Cachexia Syndrome Drug Sales Value (2021-2032)
  12. 6.6.2 North America Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Cancer Anorexia-Cachexia Syndrome Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Cancer Anorexia-Cachexia Syndrome Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Cancer Anorexia-Cachexia Syndrome Drug Sales Value (2021-2032)
  21. 6.9.2 South America Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Cancer Anorexia-Cachexia Syndrome Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Country, 2025 VS 2032
7 Cancer Anorexia-Cachexia Syndrome Drug Country-level Sales and Value Analysis
  1. 7.1 Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Country (2027-2032)
  6. 7.4 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Cancer Anorexia-Cachexia Syndrome Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Cancer Anorexia-Cachexia Syndrome Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Cancer Anorexia-Cachexia Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Viking Therapeutics Inc
  8. 8.2.1 Viking Therapeutics Inc Company Information
  9. 8.2.2 Viking Therapeutics Inc Business Overview
  10. 8.2.3 Viking Therapeutics Inc Cancer Anorexia-Cachexia Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Viking Therapeutics Inc Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio
  12. 8.2.5 Viking Therapeutics Inc Recent Developments
  13. 8.3 RaQualia Pharma Inc
  14. 8.3.1 RaQualia Pharma Inc Company Information
  15. 8.3.2 RaQualia Pharma Inc Business Overview
  16. 8.3.3 RaQualia Pharma Inc Cancer Anorexia-Cachexia Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 RaQualia Pharma Inc Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio
  18. 8.3.5 RaQualia Pharma Inc Recent Developments
  19. 8.4 PsiOxus Therapeutics Ltd
  20. 8.4.1 PsiOxus Therapeutics Ltd Company Information
  21. 8.4.2 PsiOxus Therapeutics Ltd Business Overview
  22. 8.4.3 PsiOxus Therapeutics Ltd Cancer Anorexia-Cachexia Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 PsiOxus Therapeutics Ltd Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio
  24. 8.4.5 PsiOxus Therapeutics Ltd Recent Developments
  25. 8.5 Obexia AG
  26. 8.5.1 Obexia AG Company Information
  27. 8.5.2 Obexia AG Business Overview
  28. 8.5.3 Obexia AG Cancer Anorexia-Cachexia Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Obexia AG Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio
  30. 8.5.5 Obexia AG Recent Developments
  31. 8.6 Lakewood-Amedex Inc
  32. 8.6.1 Lakewood-Amedex Inc Company Information
  33. 8.6.2 Lakewood-Amedex Inc Business Overview
  34. 8.6.3 Lakewood-Amedex Inc Cancer Anorexia-Cachexia Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Lakewood-Amedex Inc Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio
  36. 8.6.5 Lakewood-Amedex Inc Recent Developments
  37. 8.7 Incyte Corp
  38. 8.7.1 Incyte Corp Company Information
  39. 8.7.2 Incyte Corp Business Overview
  40. 8.7.3 Incyte Corp Cancer Anorexia-Cachexia Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Incyte Corp Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio
  42. 8.7.5 Incyte Corp Recent Developments
  43. 8.8 Aphios Corp
  44. 8.8.1 Aphios Corp Company Information
  45. 8.8.2 Aphios Corp Business Overview
  46. 8.8.3 Aphios Corp Cancer Anorexia-Cachexia Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Aphios Corp Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio
  48. 8.8.5 Aphios Corp Recent Developments
  49. 8.9 Aeterna Zentaris Inc
  50. 8.9.1 Aeterna Zentaris Inc Company Information
  51. 8.9.2 Aeterna Zentaris Inc Business Overview
  52. 8.9.3 Aeterna Zentaris Inc Cancer Anorexia-Cachexia Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Aeterna Zentaris Inc Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio
  54. 8.9.5 Aeterna Zentaris Inc Recent Developments
  55. 8.10 Acacia Pharma Ltd
  56. 8.10.1 Acacia Pharma Ltd Company Information
  57. 8.10.2 Acacia Pharma Ltd Business Overview
  58. 8.10.3 Acacia Pharma Ltd Cancer Anorexia-Cachexia Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Acacia Pharma Ltd Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio
  60. 8.10.5 Acacia Pharma Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cancer Anorexia-Cachexia Syndrome Drug Value Chain Analysis
  2. 9.1.1 Cancer Anorexia-Cachexia Syndrome Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cancer Anorexia-Cachexia Syndrome Drug Sales Mode & Process
  6. 9.2 Cancer Anorexia-Cachexia Syndrome Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cancer Anorexia-Cachexia Syndrome Drug Distributors
  9. 9.2.3 Cancer Anorexia-Cachexia Syndrome Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst